• Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

  • Sep 5 2024
  • Length: 30 mins
  • Podcast

Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

Listen for free

View show details

  • Summary

  • In this podcast episode, we sit down with Christopher Heery, the Chief Medical Officer at Arcellx to learn about the company's pipeline and lead cell therapy, anitocabtagene autoleucel, or anito-cel, that is in development for multiple myeloma. Multiple myeloma, like lymphoma and leukemia are types of cancer that start in your blood cells.
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Show more Show less

What listeners say about Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available